Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Purchased by 683 Capital Management LLC

683 Capital Management LLC lifted its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 14.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,400,000 shares of the company's stock after acquiring an additional 180,420 shares during the period. 683 Capital Management LLC owned 3.42% of Vigil Neuroscience worth $2,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. abrdn plc increased its holdings in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares during the period. Renaissance Technologies LLC raised its position in Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock worth $624,000 after buying an additional 321,300 shares during the last quarter. Blair William & Co. IL acquired a new stake in Vigil Neuroscience during the 4th quarter valued at approximately $551,000. Marshall Wace LLP boosted its holdings in shares of Vigil Neuroscience by 85.3% in the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock valued at $454,000 after acquiring an additional 122,853 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock worth $769,000 after acquiring an additional 66,712 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on VIGL shares. HC Wainwright lowered their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Guggenheim restated a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Wedbush reiterated an "outperform" rating and set a $13.00 price target on shares of Vigil Neuroscience in a research report on Monday. Finally, William Blair upgraded Vigil Neuroscience to a "strong-buy" rating in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $16.25.

Vigil Neuroscience Price Performance

NASDAQ VIGL remained flat at $2.41 during trading hours on Wednesday. The company had a trading volume of 72,074 shares, compared to its average volume of 479,606. The stock has a market capitalization of $118.39 million, a price-to-earnings ratio of -1.17 and a beta of 1.90. The firm has a fifty day moving average price of $1.93 and a 200-day moving average price of $2.34. Vigil Neuroscience, Inc. has a 12 month low of $1.31 and a 12 month high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, sell-side analysts expect that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.